Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.
about
Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisNew treatments for ulcerative colitis: do we have pediatric data?Highlights in IBD Epidemiology and Its Natural History in the Paediatric Age.Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.Drug Development of Therapeutic Monoclonal Antibodies.Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.
P2860
Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@en
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@nl
type
label
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@en
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@nl
prefLabel
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@en
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@nl
P2093
P2860
P1476
Outcomes following infliximab ...... ctory colitis-predominant IBD.
@en
P2093
Benjamin R Saville
Dedrick E Moulton
Keisha R Mitchell
Michael J Rosen
Sara N Horst
Tolulope O Falaiye
P2860
P304
P356
10.1097/MPG.0B013E3182A98DF2
P407
P577
2014-02-01T00:00:00Z